TG Therapeutics (TGTX) News Today → $5,000 Gold? (From Stansberry Research) (Ad) Free TGTX Stock Alerts $16.58 +0.70 (+4.41%) (As of 01:34 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineTG Therapeutics (NASDAQ:TGTX) Releases Earnings Results, Misses Estimates By $0.02 EPSmarketbeat.com - May 2 at 12:36 PMTG Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lagsfinance.yahoo.com - May 2 at 11:05 AMTG Therapeutics (NASDAQ:TGTX) PT Raised to $40.00marketbeat.com - May 2 at 9:11 AMQ2 2024 EPS Estimates for TG Therapeutics, Inc. Raised by B. Riley (NASDAQ:TGTX)marketbeat.com - May 2 at 7:49 AMTG Therapeutics, Inc. to Post FY2026 Earnings of $1.60 Per Share, B. Riley Forecasts (NASDAQ:TGTX)americanbankingnews.com - May 2 at 2:38 AMTG Therapeutics Target of Unusually High Options Trading (NASDAQ:TGTX)americanbankingnews.com - May 2 at 1:38 AMQ1 2024 TG Therapeutics Inc Earnings Call Transcriptgurufocus.com - May 2 at 1:01 AMHold Rating on TG Therapeutics Amidst Strong Briumvi Launch and Competitive Market Pressuresmarkets.businessinsider.com - May 1 at 11:37 PMTG Therapeutics Shares Rise 27% After 1Q Revenue Beatmarketwatch.com - May 1 at 1:36 PMTG Therapeutics Inc. Q1 Loss decreases, but misses estimatesmarkets.businessinsider.com - May 1 at 1:36 PMTG Therapeutics jumps as Q1 Briumvi sales top guidancemsn.com - May 1 at 1:36 PMTG Therapeutics Inc (TGTX) Surpasses Revenue Estimates in Q1 2024, Despite Widening Net Lossfinance.yahoo.com - May 1 at 1:36 PMTG Therapeutics Target of Unusually Large Options Trading (NASDAQ:TGTX)marketbeat.com - May 1 at 1:22 PMTGTX Stock Earnings: TG Therapeutics Misses EPS, Beats Revenue for Q1 2024investorplace.com - May 1 at 1:02 PMTG Therapeutics (NASDAQ:TGTX) Shares Gap Up to $13.66marketbeat.com - May 1 at 12:28 PMTG Therapeutics, Inc. (NASDAQ:TGTX) Forecasted to Post FY2026 Earnings of $1.60 Per Sharemarketbeat.com - May 1 at 8:59 AMTG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Resultsglobenewswire.com - May 1 at 7:00 AMTG Therapeutics to Host Conference Call on First Quarter 2024 Financial Results and Business Updateglobenewswire.com - April 30 at 4:55 PMBank of America Securities Keeps Their Sell Rating on TG Therapeutics (TGTX)markets.businessinsider.com - April 23 at 7:42 PMTG Therapeutics (NASDAQ:TGTX) Stock Price Up 4.8%marketbeat.com - April 18 at 4:55 PMTG Therapeutics (NASDAQ:TGTX) Earns "Overweight" Rating from JPMorgan Chase & Co.marketbeat.com - April 18 at 2:21 PMTG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meetingglobenewswire.com - April 18 at 7:30 AMTG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosisglobenewswire.com - April 18 at 7:00 AMTG Therapeutics: The Cloud Over Briumviseekingalpha.com - April 17 at 10:24 AMTG Posts Gains on Results of MS Drug Testmsn.com - April 15 at 1:50 PMTG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meetingglobenewswire.com - April 15 at 7:30 AMTG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meetingglobenewswire.com - April 15 at 7:30 AMTG Therapeutics Breaks Below 200-Day Moving Average - Notable for TGTXnasdaq.com - April 14 at 8:16 PMTG Therapeutics, Inc. (NASDAQ:TGTX) Receives Average Recommendation of "Moderate Buy" from Brokeragesmarketbeat.com - April 14 at 2:12 AMTG Therapeutics: BRIUMVI Development Could Lead To Great Resultsseekingalpha.com - April 12 at 8:00 PMTG Therapeutics, Inc. (NASDAQ:TGTX) Receives Consensus Rating of "Moderate Buy" from Brokeragesmarketbeat.com - March 20 at 3:41 AMIs TG Therapeutics, Inc.'s (NASDAQ:TGTX) Recent Price Movement Underpinned By Its Weak Fundamentals?finance.yahoo.com - March 19 at 10:29 AMTg therapeutics director sells shares worth over $79kinvesting.com - March 17 at 9:24 AMTGTX Mar 2024 20.500 callfinance.yahoo.com - March 16 at 1:08 PMTGTX Mar 2024 16.500 putfinance.yahoo.com - March 16 at 1:08 PMTGTX Apr 2024 19.500 callfinance.yahoo.com - March 16 at 3:07 AMTGTX Apr 2024 11.000 putfinance.yahoo.com - March 16 at 3:07 AMTGTX Apr 2024 23.000 callfinance.yahoo.com - March 15 at 5:06 PMTGTX Apr 2024 16.000 putfinance.yahoo.com - March 15 at 5:06 PMJacobs Levy Equity Management Inc. Purchases 145,667 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)marketbeat.com - March 15 at 4:16 AMLaurence N. Charney Sells 22,000 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) Stockinsidertrades.com - March 14 at 9:39 AMTG Therapeutics (NASDAQ:TGTX) Shares Down 3.9% marketbeat.com - March 8 at 1:45 PMTG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meetingglobenewswire.com - March 8 at 7:30 AMFmr LLC Lowers Position in TG Therapeutics, Inc. (NASDAQ:TGTX)marketbeat.com - March 8 at 4:25 AMValidea Detailed Fundamental Analysis - TGTXnasdaq.com - March 6 at 4:14 PMTGTX Mar 2024 19.500 callfinance.yahoo.com - March 3 at 6:20 PMTGTX Mar 2024 18.000 putfinance.yahoo.com - March 3 at 6:20 PMSchonfeld Strategic Advisors LLC Has $11.43 Million Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)marketbeat.com - March 3 at 8:20 AM683 Capital Management LLC Invests $11.29 Million in TG Therapeutics, Inc. (NASDAQ:TGTX)marketbeat.com - March 1 at 10:35 AMTG Therapeutics: Briumvi Growth Story Appears Intactseekingalpha.com - March 1 at 8:50 AM Get TG Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TGTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Gold Mania (Ad)Former Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite). See his free reveal right here. TGTX Media Mentions By Week TGTX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TGTX News Sentiment▼0.090.33▲Average Medical News Sentiment TGTX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TGTX Articles This Week▼245▲TGTX Articles Average Week Get TG Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TGTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Dyne Therapeutics News Vera Therapeutics News Rocket Pharmaceuticals News Arvinas News Corcept Therapeutics News Merus News Avidity Biosciences News Amphastar Pharmaceuticals News Rhythm Pharmaceuticals News Keros Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TGTX) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersAI finds its first serious applicationWall Street StarRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsProtect Your Bank Account Before It’s Too LateWeiss RatingsYour bank is lying to you.MyBankTrackerTruth about Trump you’ve never heardPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TG Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
